| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
The Prostate Centre, Vancouver General Hospital, 2660 Oak Street, Vancouver, British Columbia V6H 3Z6 [H. M., C. N., P. S. R., M. E. G.], and Division of Urology, University of British Columbia, D-9, 2733 Heather Street, Vancouver, British Columbia V5Z 3J5 [H. M., C. N., M. E. G.], Canada
Testosterone-repressed prostate message-2 (TRPM-2) expression is highly up-regulated in normal and malignant prostate cells after androgen withdrawal. Although recent studies have suggested a protective role of TRPM-2 expression against apoptosis in several experimental models, the functional role of TRPM-2 in chemotherapy-induced apoptosis remains undefined. Here, we demonstrated that overexpression of TRPM-2 in human androgen-dependent LNCaP prostate cancer cells by stable transfection rendered them highly resistant to paclitaxel treatment than control LNCaP cells, with a 20-fold higher IC50 through the inhibition of apoptotic cell death. In mice bearing TRPM-2-overexpressing LNCaP tumors, tumor volume and serum prostate-specific antigen increased two to three times faster after castration and paclitaxel treatment compared with mice bearing control tumors. We then tested the efficacy of combined treatment with antisense TRPM-2 oligodeoxynucleotide (ODN) and paclitaxel in the mouse androgen-dependent Shionogi tumor model. Antisense TRPM-2 ODN treatment significantly enhanced paclitaxel chemosensitivity of Shionogi tumor cells in a dose-dependent manner, reducing the IC50 by 75%. Combined treatment of Shionogi cells with 500 nM antisense TRPM-2 ODN and 10 nM paclitaxel-induced apoptosis, either agent alone did not. Adjuvant administration of antisense TRPM-2 ODN and polymeric micellar paclitaxel after castration resulted in reduced TRPM-2 levels in vivo and a significant delay of emergence of androgen-independent recurrent Shionogi tumors compared with administration of either agent alone. Furthermore, combined treatment of mice bearing androgen-independent recurrent Shionogi tumors with antisense TRPM-2 ODN and micellar paclitaxel inhibited tumor growth compared with treatment with either agent alone. Collectively, these findings demonstrate that TRPM-2 overexpression helps confer a chemoresistant phenotype through inhibition of apoptosis, and that antisense TRPM-2 ODN may be useful in enhancing the effects of cytotoxic chemotherapy in hormone-refractory prostate cancer.
This article has been cited by other articles:
|
|
 |
|
  D. Kevans, J. Foley, M. Tenniswood, K. Sheahan, J. Hyland, D. O'Donoghue, H. Mulcahy, and J. O'Sullivan High Clusterin Expression Correlates with a Poor Outcome in Stage II Colorectal Cancers Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 393 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ammar and J. L. Closset Clusterin Activates Survival through the Phosphatidylinositol 3-Kinase/Akt Pathway J. Biol. Chem., May 9, 2008; 283(19): 12851 - 12861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Sallman, X. Chen, B. Zhong, D. L. Gilvary, J. Zhou, S. Wei, and J. Y. Djeu Clusterin mediates TRAIL resistance in prostate tumor cells Mol. Cancer Ther., November 1, 2007; 6(11): 2938 - 2947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. To, Y. Zhao, H. Jiang, K. Hu, M. Wang, J. Wu, C. Lee, D. W. Yokom, A. L. Stratford, U. Klinge, et al. The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor Mol. Pharmacol., September 1, 2007; 72(3): 641 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Andersen, T. Schepeler, K. Thorsen, K. Birkenkamp-Demtroder, F. Mansilla, L. A. Aaltonen, S. Laurberg, and T. F. Orntoft Clusterin Expression in Normal Mucosa and Colorectal Cancer Mol. Cell. Proteomics, June 1, 2007; 6(6): 1039 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kamada, A. So, M. Muramaki, P. Rocchi, E. Beraldi, and M. Gleave Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 299 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Cheng, R. Snoek, F. Ghaidi, M. E. Cox, and P. S. Rennie Short Hairpin RNA Knockdown of the Androgen Receptor Attenuates Ligand-Independent Activation and Delays Tumor Progression Cancer Res., November 1, 2006; 66(21): 10613 - 10620. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Rodriguez-Pineiro, M. P. de la Cadena, A. Lopez-Saco, and F. J. Rodriguez-Berrocal Differential Expression of Serum Clusterin Isoforms in Colorectal Cancer Mol. Cell. Proteomics, September 1, 2006; 5(9): 1647 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Thomas, S. Chigurupati, M. Anbalagan, and G. Shah Calcitonin Increases Tumorigenicity of Prostate Cancer Cells: Evidence for the Role of Protein Kinase A and Urokinase-Type Plasminogen Receptor Mol. Endocrinol., August 1, 2006; 20(8): 1894 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, P. Rocchi, H. Miyake, L. Fazli, B. Vessella, U. Zangemeister-Wittke, and M. E. Gleave A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells Mol. Cancer Ther., November 1, 2005; 4(11): 1689 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Criswell, M. Beman, S. Araki, K. Leskov, E. Cataldo, L. D. Mayo, and D. A. Boothman Delayed Activation of Insulin-like Growth Factor-1 Receptor/Src/MAPK/Egr-1 Signaling Regulates Clusterin Expression, a Pro-survival Factor J. Biol. Chem., April 8, 2005; 280(14): 14212 - 14221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamanaka, M. E. Gleave, I. Hara, M. Muramaki, and H. Miyake Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model Mol. Cancer Ther., February 1, 2005; 4(2): 187 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Caporali, P. Davalli, S. Astancolle, D. D'Arca, M. Brausi, S. Bettuzzi, and A. Corti The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression Carcinogenesis, November 1, 2004; 25(11): 2217 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bayon, M. A. Ortiz, F. J. Lopez-Hernandez, P. H. Howe, and F. J. Piedrafita The Retinoid Antagonist MX781 Induces Clusterin Expression in Prostate Cancer Cells via Heat Shock Factor-1 and Activator Protein-1 Transcription Factors Cancer Res., August 15, 2004; 64(16): 5905 - 5912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. P. Trougakos, A. So, B. Jansen, M. E. Gleave, and E. S. Gonos Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress Cancer Res., March 1, 2004; 64(5): 1834 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. V. July, E. Beraldi, A. So, L. Fazli, K. Evans, J. C. English, and M. E. Gleave Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo Mol. Cancer Ther., March 1, 2004; 3(3): 223 - 232. [Abstract] [Full Text]
|
|
|
|
|
|
K. S. Leskov, D. Y. Klokov, J. Li, T. J. Kinsella, and D. A. Boothman Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein J. Biol. Chem., March 21, 2003; 278(13): 11590 - 11600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zellweger, K. Chi, H. Miyake, H. Adomat, S. Kiyama, K. Skov, and M. E. Gleave Enhanced Radiation Sensitivity in Prostate Cancer by Inhibition of the Cell Survival Protein Clusterin Clin. Cancer Res., October 1, 2002; 8(10): 3276 - 3284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Deng, H. K. Parekh, K.-C. Chow, and H. Simpkins Increased Expression of Dihydrodiol Dehydrogenase Induces Resistance to Cisplatin in Human Ovarian Carcinoma Cells J. Biol. Chem., April 19, 2002; 277(17): 15035 - 15043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. Shultz, S. Phillips, M. Sar, P. M. D. Foster, and K. W. Gaido Altered Gene Profiles in Fetal Rat Testes after in Utero Exposure to Di(n-butyl) Phthalate Toxicol. Sci., December 1, 2001; 64(2): 233 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Miyake, I. Hara, S. Kamidono, and M. E. Gleave Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodeoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model Clin. Cancer Res., December 1, 2001; 7(12): 4245 - 4252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zellweger, H. Miyake, S. Cooper, K. Chi, B. S. Conklin, B. P. Monia, and M. E. Gleave Antitumor Activity of Antisense Clusterin Oligonucleotides Is Improved in Vitro and in Vivo by Incorporation of 2'-O-(2-Methoxy)Ethyl Chemistry J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 934 - 940. [Abstract] [Full Text]
|
|
|
|
|
|
X.S. Ouyang, X. Wang, D.T.W. Lee, S.W. Tsao, and Y.C. Wong Up-regulation of TRPM-2, MMP-7 and ID-1 during sex hormone-induced prostate carcinogenesis in the Noble rat Carcinogenesis, June 1, 2001; 22(6): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
